kyoto.jpeg

kyoto

kyotovisitorshost.jpeg

kyotovisitorshost

General information

Announcements(0)

Overview

Pre-registration

Abstract Submission (Oral/Poster Presentation)

Guidelines for Writing Abstracts (Oral/Poster Pres

Program

Sessions

Search presentations

pharm140_e.png

icon_20251203154432448.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

A password that applicants have been notified of is required to view abstracts. If you are a participant and need to confirm the password, please contact us by e-mail about which annual meeting you would like to know the password for to view abstracts. We will reply after confirming that you were a participant. Thank you for your understanding.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Program Type

Profile management

Announcements

Bookmark

Download PDF for print

Timetable

Safe and accelerated provision of pharmaceuticals - Outline of amendments to the Pharmaceuticals and Medical Devices Act

In his Dialectics of Nature, the German philosopher Friedrich Engels described the transformation of quality and quantity as the "mutual penetration of polar opposites and transformation into each other when carried to extremes." This raises the question of whether regulations are a roadblock for innovation. Medical products must be developed in accordance with regulatory frameworks to ensure their quality, effectiveness, and safety. After approval, medical devices are subject to a regulatory framework for post-marketing surveillance. A regulatory framework is needed to ensure that patients have access to safe medical products. However, sometimes, a series of regulatory frameworks ends up acting as a roadblock for, and thereby preventing, medical innovation, leading to delayed patient access to innovative products. By contrast, when regulation is optimal, it is not roadblock; rather, it is the actual pathway to achieving real and lasting innovation (Margaret Hamburg, Feb 2012). In this symposium, symposiasts from regulatory authorities, academia, and industry will speak about recent topics in regard to the development and/or regulation of medical products. Subsequently, we will discuss the current status of harmonization between regulation and innovation with pharmacists and pharmaceutical scientists. We hope that this symposium will serve to promote interpenetration between the regulation and innovation of medical products, leading to initiatives for medical innovation in Japan.

Harmonization of pharmaceutical regulation and innovation

The 140th Annual Meeting of the Pharmaceutical Society of Japan (Kyoto)

Presentation Information

[S03-1]Safe and accelerated provision of pharmaceuticals - Outline of amendments to the Pharmaceuticals and Medical Devices Act

Password required to view